CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease

VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, announces the treatment of the first patient in its Phase 2 clinical trial for Graft versus Host Disease (GvHD), its leading immunologic indication for PRO 140. GvHD is a potentially life-threatening complication in patients requiring a bone marrow transplant because their immune systems have been depleted during aggressive cancer therapy for
http://bit.ly/2rqvQbw